Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index-Reference-Cited by-同舟云学术

Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index

Published:2022-06 Issue:18 Volume:18 Page:2269-2288
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Zhao Man¹^ORCID,Duan Xiaoling¹,Mi Lili¹,Shi Jianfei¹^ORCID,Li Ning¹,Yin Xiaolei¹,Han Xin¹,Wang Jinfeng¹,Han Guangjie¹,Hou Jiaojiao¹,Yin Fei¹

Affiliation:

1. Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Heibei, PR China

Abstract

Aim: To explore the prognostic value of the systemic inflammatory response index (SIRI) and peripheral blood T-cell subsets in patients with hepatocellular carcinoma (HCC) and the relationship between them. Materials & methods: We treated 352 patients with HCC with sorafenib and/or immune checkpoint inhibitors (ICIs) and analyzed SIRI and peripheral blood T cells. Results: SIRI was an independent prognostic factor for patients with HCC receiving systemic therapy. Patients with high SIRI and low baseline peripheral blood T-cell counts showed a poor response to ICIs. SIRI was significantly and negatively correlated with CD3+, CD4+ and CD8+ T-cell counts. Conclusion: SIRI markers can be employed to noninvasively assess the presence of cancer-promoting inflammation in the tumor microenvironment and predict the efficacy of targeted therapy and immunotherapy.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-1087

Reference58 articles.

1. A global view of hepatocellular carcinoma: trends, risk, prevention and management

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

4. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity

5. ClinicalTrials.gov. Safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus lenvatinib as first-line therapy in participants with advanced hepatocellular carcinoma (MK-7902–002/E7080-G000–311/LEAP-002). Accessed 15 December 2019. https://clinicaltrials.gov/ct2/show/NCT03713593

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma;Frontiers in Immunology;2023-12-22

2. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors;BMC Cancer;2023-12-01

3. Postchemoradiotherapy systemic inflammation response index predicts treatment response and overall survival for patients with locally advanced nasopharyngeal cancer;Journal of the Formosan Medical Association;2023-11

4. Prognostic significance of the systemic inflammation response index in gastrointestinal malignancy patients: a pooled analysis of 10,091 participants;Future Oncology;2023-09

5. PD-L1 expression, morphology, and molecular characteristic of a subset of aggressive uterine tumor resembling ovarian sex cord tumor and a literature review;Journal of Ovarian Research;2023-05-23